Alzheimer’s disease (AD) has minimally effective treatments currently. High concentrations of resveratrol, a polyphenol antioxidant found in plants, have been reported to affect several AD-related and neuroprotective genes. To address the low bioavailability of resveratrol, we investigated a novel oral formulation of resveratrol, JOTROL™, that has shown increased pharmacokinetic properties compared to non-formulated resveratrol in animals and in humans.
Objective:
We hypothesized that equivalent doses of JOTROL, compared to non-formulated resveratrol, would result in greater brain exposure to resveratrol, and more efficacious responses on AD biomarkers.
Methods:
For sub-chronic reversal studies, 15-month-old male triple transgenic (APPSW/PS1M146V/TauP301L; 3xTg-AD) AD mice were treated orally with vehicle or 50 mg/kg JOTROL for 36 days. For prophylactic studies, male and female 3xTg-AD mice were similarly administered vehicle, 50 mg/kg JOTROL, or 50 mg/kg resveratrol for 9 months starting at 4 months of age. A behavioral battery was run, and mRNA and protein from brain and blood were analyzed for changes in AD-related gene and protein expression.
Results:
JOTROL displays significantly increased bioavailability over non-formulated resveratrol. Treatment with JOTROL resulted in AD-related gene expression changes (Adam10, Bace1, Bdnf, Psen1) some of which were brain region-dependent and sex-specific, as well as changes in inflammatory gene and cytokine levels.
Conclusion:
JOTROL may be effective as a prophylaxis and/or treatment for AD through increased expression and/or activation of neuroprotective genes, suppression of pro-inflammatory genes, and regulation of central and peripheral cytokine levels.
JhangKA, ParkJS, KimHS, ChongYH (2017) Resveratrol ameliorates tau hyperphosphorylation at Ser396 site and oxidative damage in rat hippocampal slices exposed to vanadate: Implication of ERK1/2 and GSK-3β signaling cascades. J Agric Food Chem65, 9626–9634.
10.
AshrafizadehM, ZarrabiA, NajafiM, SamarghandianS, MohammadinejadR, AhnKS (2020) Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: An updated review. Phytother Res34, 2867–2888.
11.
GarrigueP, MounienL, ChampionS, MouhajirY, PechereL, GuilletB, LandrierJF, SereeE (2021) Long-term administration of resveratrol at low doses improves neurocognitive performance as well as cerebral blood flow and modulates the inflammatory pathways in the brain. J Nutr Biochem97, 108786.
12.
LamYY, PetersonCM, RavussinE (2013) Resveratrol vs. calorie restriction: Data from rodents to humans. Exp Gerontol48, 1018–1024.
13.
AlbaniD, PolitoL, ForloniG (2010) Sirtuins as novel targets for Alzheimer’s disease and other neurodegenerative disorders: Experimental and genetic evidence. J Alzheimers Dis19, 11–26.
14.
KulkarniS, CantoC (2015) The molecular targets of resveratrol. Biochim Biophys Acta1852, 1114–1123.
15.
RahmanMH, AkterR, BhattacharyaT, Abdel-DaimMM, AlkahtaniS, ArafahMW, Al-JohaniNS, AlhoshaniNM, AlkeraishanN, AlhenakyA, Abd-ElkaderOH, El-SeediHR, KaushikD, MittalV (2020) Resveratrol and neuroprotection: Impact and its therapeutic potential in Alzheimer’s disease. Front Pharmacol11, 619024.
16.
WalleT, HsiehF, DeLeggeMH, OatisJE, WalleUK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos32, 1377–1382.
17.
TurnerRS, ThomasRG, CraftS, van DyckCH, MintzerJ, ReynoldsBA, BrewerJB, RissmanRA, RamanR, AisenPS; Alzheimer’s Disease Cooperative Study (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology85, 1383–1391.
OddoS, CaccamoA, KitazawaM, TsengBP, LaFerlaFM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging24, 1063–1070.
21.
National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals, National Academies Press (US), Washington, DC.
22.
BaileyKR, CrawleyJN (2009) Anxiety-related behaviors in mice. In Methods of Behavior Analysis in Neuroscience, BuccafuscoJJ, ed. CRC Press/Taylor & Francis, CRC Press.
23.
TuckerLB, McCabeJT (2017) Behavior of male and female C57BL/6J mice is more consistent with repeated trials in the elevated zero maze than in the elevated plus maze. Front Behav Neurosci11, 13.
24.
LegerM, QuiedevilleA, BouetV, HaelewynB, BoulouardM, Schumann-BardP, FreretT (2013) Object recognition test in mice. Nat Protoc8, 2531–2537.
25.
GawelK, GibulaE, Marszalek-GrabskaM, FilarowskaJ, KotlinskaJH (2019) Assessment of spatial learning and memory in the Barnes maze task in rodents— methodological consideration. Naunyn Schmiedebergs Arch Pharmacol392, 1–18.
26.
JavonilloDI, TranKM, PhanJ, HingcoE, KramárEA, CunhaC da, FornerS, KawauchiS, NeumannJ, BanhCE, HuynhM, MatheosDP, RezaieN, AlcantaraJA, MortazaviA, WoodMA, TennerAJ, MacGregorGR, GreenKN, LaFerlaFM (2021) Systematic phenotyping and characterization of the 3xTg-AD mouse model of Alzheimer’s disease. bioRxiv 2021.10.01.462640; doi: https://doi.org/10.1101/2021.10.01.462640.
27.
BlaserR, HeyserC (2015) Spontaneous object recognition: A promising approach to the comparative study of memory. Front Behav Neurosci9, 183.
28.
Hirata-FukaeC, LiHF, HoeHS, GrayAJ, MinamiSS, HamadaK, NiikuraT, HuaF, Tsukagoshi-NagaiH, Horikoshi-SakurabaY, MughalM, RebeckGW, LaFerlaFM, MattsonMP, IwataN, SaidoTC, KleinWL, DuffKE, AisenPS, MatsuokaY (2008) Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res1216, 92–103.
29.
HeppnerFL, RansohoffRM, BecherB (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci16, 358–372.
30.
BroderickTL, RasoolS, LiR, ZhangY, AndersonM, Al-NakkashL, PlochockiJH, GeethaT, BabuJR (2020) Neuroprotective effects of chronic resveratrol treatment and exercise training in the 3xTg-AD mouse model of Alzheimer’s disease. Int J Mol Sci21, 7337.
31.
SharmaM, GuptaYK (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci71, 2489–2498.
32.
ChenY, ShiGW, LiangZM, ShengSY, ShiYS, PengL, WangYP, WangF, ZhangXM (2019) Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice. Mol Med Rep19, 3783–3790.
33.
AbrahamJ, JohnsonRW (2009) Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res12, 445–453.
34.
HaradaN, ZhaoJ, KuriharaH, NakagataN, OkajimaK (2011) Resveratrol improves cognitive function in mice by increasing production of insulin-like growth factor-I in the hippocampus. J Nutr Biochem22, 1150–1159.
35.
PorquetD, CasadesúsG, BayodS, VicenteA, CanudasAM, VilaplanaJ, PelegríC, SanfeliuC, CaminsA, PallàsM, del ValleJ (2013) Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. Age (Dordr)35, 1851–1865.
36.
ParkHR, KongKH, YuBP, MattsonMP, LeeJ (2012) Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J Biol Chem287, 42588–42600.
CorpasR, Griñán-FerréC, Rodríguez-FarréE, PallàsM, SanfeliuC (2019) Resveratrol induces brain resilience against Alzheimer neurodegeneration through proteostasis enhancement. Mol Neurobiol56, 1502–1516.
39.
KaruppagounderSS, PintoJT, XuH, ChenHL, BealMF, GibsonGE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int54, 111–118.
40.
VaraminiB, SikalidisAK, BradfordKL (2014) Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: An exploratory study. Int J Food Sci Nutr65, 89–96.
41.
MinSW, ChoSH, ZhouY, SchroederS, HaroutunianV, SeeleyWW, HuangEJ, ShenY, MasliahE, MukherjeeC, MeyersD, ColePA, OttM, GanL (2010) Acetylation of Tau inhibits its degradation and contributes to tauopathy. Neuron67, 953–966.
42.
DongYT, CaoK, TanLC, WangXL, QiXL, XiaoY, GuanZZ (2018) Stimulation of SIRT1 attenuates the level of oxidative stress in the brains of APP/PS1 double transgenic mice and in primary neurons exposed to oligomers of the Amyloid-β Peptide. J Alzheimers Dis63, 283–301.
43.
ChangJ, RimandoA, PallasM, CaminsA, PorquetD, ReevesJ, Shukitt-HaleB, SmithMA, JosephJA, CasadesusG (2012) Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer’s disease. Neurobiol Aging33, 2062–2071.
KamphuisW, KooijmanL, OrreM, StassenO, PeknyM, HolEM (2015) GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer’s disease. Glia63, 1036–1056.
46.
YehCY, VadhwanaB, VerkhratskyA, RodríguezJJ (2011) Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro3, 271–279.
47.
OlabarriaM, NoristaniHN, VerkhratskyA, RodríguezJJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia58, 831–838.
48.
DennisonJL, RicciardiNR, LohseI, VolmarCH, WahlestedtC (2021) Sexual dimorphism in the 3xTg-AD mouse model and its impact on pre-clinical research. J Alzheimers Dis80, 41–52.
49.
StimmellAC, Baglietto-VargasD, MoseleySC, LapointeV, ThompsonLM, LaFerlaFM, McNaughtonBL, WilberAA (2019) Impaired spatial reorientation in the 3xTg-AD mouse model of Alzheimer’s disease. Sci Rep9, 1311.
50.
YangJT, WangZJ, CaiHY, YuanL, HuMM, WuMN, QiJS (2018) Sex differences in neuropathology and cognitive behavior in APP/PS1/tau triple-transgenic mouse model of Alzheimer’s disease. Neurosci Bull34, 736–746.
51.
BlázquezG, CañeteT, TobeñaA, Giménez-LlortL, Fernández-TeruelA (2014) Cognitive and emotional profiles of aged Alzheimer’s disease (3×TgAD) mice: Effects of environmental enrichment and sexual dimorphism. Behav Brain Res268, 185–201.
52.
CarrollJC, RosarioER, KreimerS, VillamagnaA, GentzscheinE, StanczykFZ, PikeCJ (2010) Sex differences in β-amyloid accumulation in 3xTg-AD mice: Role of neonatal sex steroid hormone exposure. Brain Res1366, 233–245.
53.
GehmBD, McAndrewsJM, ChienPY, JamesonJL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen-receptor. Proc Natl Acad Sci U S A94, 14138–14143.
54.
YangJA, StiresH, BeldenWJ, RoepkeTA (2017) The arcuate estrogen-regulated transcriptome: Estrogen response element–dependent and – independent signaling of ERα in female mice. Endocrinology158, 612–626.
55.
AlexanderA, IrvingAJ, HarveyJ (2017) Emerging roles for the novel estrogen-sensing receptor GPER1 in the CNS. Neuropharmacology113(Pt B), 652–660.
56.
GonzálezM, Cabrera-SocorroA, Pérez-GarcíaCG, FraserJD, LópezFJ, AlonsoR, MeyerG (2007) Distribution patterns of estrogen receptor α and β in the human cortex and hippocampus during development and adulthood. J Comp Neurol503, 790–802.
57.
LlorenteR, MarraudinoM, CarrilloB, BonaldoB, Simon-ArecesJ, Abellanas-PérezP, Rivero-AguilarM, Fernandez-GarciaJM, PinosH, Garcia-SeguraLM, ColladoP, GrassiD (2020) G protein-coupled estrogen receptor immunoreactivity fluctuates during the estrous cycle and show sex differences in the amygdala and dorsal hippocampus. Front Endocrinol11, 537.
58.
MalaguarneraL (2019) Influence of resveratrol on the immune response. Nutrients11, 946.
59.
KleinSL, FlanaganKL (2016) Sex differences in immune responses. Nat Rev Immunol16, 626–638.
60.
WaxmanDJ, HollowayMG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol76, 215–228.
61.
NishidaY, YoshiokaM, St-AmandJ (2005) Sexually dimorphic gene expression in the hypothalamus, pituitary gland, and cortex. Genomics85, 679–687.
62.
McCarthyMM, AugerAP, BaleTL, De VriesGJ, DunnGA, ForgerNG, MurrayEK, NugentBM, SchwarzJM, WilsonME (2009) The epigenetics of sex differences in the brain. J Neurosci29, 12815–12823.
